'Information theory' recruited to help scientists find cancer genes
(Johns Hopkins Medicine) Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: news

Diet, Exercise Intervention Explored in Children With B-ALL
THURSDAY, April 8, 2021 -- For children with B-cell acute lymphoblastic leukemia (B-ALL), a diet and exercise intervention might improve disease response, according to a study published online April 1 in Blood Advances. Etan Orgel, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

What are the risk factors for experiencing side effects from childhood cancer treatments?
(Wiley) Steroids are essential for treating children with acute lymphoblastic leukemia, a type of cancer of the blood and bone marrow, but they can cause severe side effects such as psychological reactions and sleep problems. An analysis published in Psycho-Oncology of all relevant studies published to date indicates that there's insufficient high-quality research investigating the risk factors for these side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2021 Category: International Medicine & Public Health Source Type: news

Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia
FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests. Acute lymphoblastic leukemia is the most common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 2, 2021 Category: General Medicine Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.Now,a study led by researchers at UCLA and Children’s Hospital Los Angeles has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program imm...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Stem cell transplants prevent relapses of most common childhood cancer
(University of Virginia Health System) Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
(University of California - Los Angeles Health Sciences) A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 4, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Genetic Mutations May Add to Racial Disparity in Child B-ALL
FRIDAY, Feb. 19, 2021 -- Hispanic/Latino (H/L) children with B-cell acute lymphoblastic leukemia (B-ALL) have an increased incidence of IKZF1 deletion and IGH-CRLF2 translocation, according to a letter to the editor published online Feb. 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

TBI Beats Chemoconditioning for ALL Transplants in Children TBI Beats Chemoconditioning for ALL Transplants in Children
Total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing transplant for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Highlights in Acute Lymphoblastic Leukemia From ASH 2020 Highlights in Acute Lymphoblastic Leukemia From ASH 2020
Key studies from ASH 2020 on acute lymphoblastic leukemia include novel CAR T-cells, antibody-based therapies sequenced with chemotherapy, and residual disease monitoring with peripheral blood.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Chemotherapy and blinatumomab improves survival for patients with B-cell acute lympho
(University of Texas M. D. Anderson Cancer Center) A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Survival Rate for Acute Lymphoblastic Leukemia
Title: Survival Rate for Acute Lymphoblastic LeukemiaCategory: Diseases and ConditionsCreated: 10/23/2020 12:00:00 AMLast Editorial Review: 10/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 23, 2020 Category: Cancer & Oncology Source Type: news

' Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL
Chemo-free targeted therapy yielded high rates of molecular response,"impressive" survival at 18 months with few toxic effects in a phase 2 trial of adults with Ph+ acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Orthopedic Problems in Children Can Be the First Sign of ALL Orthopedic Problems in Children Can Be the First Sign of ALL
The diagnosis of acute lymphoblastic leukemia (ALL) can be delayed because of vague presentation and normal hematological results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 2, 2020 Category: Cancer & Oncology Tags: Pediatrics News Source Type: news

New NCCN resource for understanding childhood leukemia
(National Comprehensive Cancer Network) NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 23, 2020 Category: Cancer & Oncology Source Type: news

Inherited genetic variant influences response to leukemia treatment for some children
(St. Jude Children's Research Hospital) St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology. Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
FRIDAY, July 31, 2020 -- Survivors of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) may experience late effects, with a high incidence of subsequent endocrine disease and cardiac disease, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

A spin-off to develop therapies for leukaemia based on CAR-T, by Josep Carreras Institute
(Josep Carreras Leukaemia Research Institute) Invivo Ventures, CDTI-Innvierte (Spanish Ministry of Industry) and the Josep Carreras Foundation have established a first round of funding of € 3,050,000. OCI will carry out three projects, the most advanced of which is a CAR-T CD1a (OCI-1) project for the treatment of cortical T-cell acute lymphoblastic leukemia (coT-ALL), a subtype of leukaemia that mainly affects children and which has a poor prognosis if patients do not respond to standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2020 Category: International Medicine & Public Health Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
TUESDAY, June 30, 2020 -- Diets high in antioxidant-rich foods may cut the risk of developing bacterial infections or mucositis during the first phase of acute lymphoblastic leukemia (ALL) treatment in pediatric patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Treating leukaemia more effectively
(Goethe University Frankfurt) Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine. The drug has not been successful, however, with B-ALL, a subtype resembling B-lymphocytes. This has puzzled oncologists sinced the 1980's. Now, an international research team headed by Goethe University and the University of Kent has discovered the reason: B-ALL cells contain the enzyme SAMHD1, which deactivates the drug. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 24, 2020 Category: Biology Source Type: news

What if child maltreatment were childhood leukemia? Lessons from the halls of the hospital - Babcock P.
This article examines lessons that can be applied to prevention, research, training, and clinical treatment in child welfare from analogous experiences in combatting childhood acute lymphoblastic leukemia (ALL). Since the 1960s, childhood cancer researcher... (Source: SafetyLit)
Source: SafetyLit - June 9, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL
A universal chimeric antigen receptor (CAR) T-cell therapy produced responses in adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) in initial findings from an ongoing study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo
A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First-in-Human Trial of TruUCAR GC027 in Relapsed/Refractory T-Cell ALL Announced
The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Discovered the physiological mechanisms underlying the most common pediatric Leukemia
(Josep Carreras Leukaemia Research Institute) Researchers from the Josep Carreras Leukaemia Research Institute unveil the mechanisms that lead to hyperdiploid Acute Lymphoblastic Leukemia, Hyper D-ALL, the most common pediatric B-cell Leukaemia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2020 Category: Biology Source Type: news

Study reveals properties of cells fated to relapse in acute lymphoblastic leukemia
(St. Jude Children's Research Hospital) Researchers have found that genetically defined subpopulations of leukemia cells present at diagnosis have distinct characteristics that lead to relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 3, 2020 Category: Cancer & Oncology Source Type: news

Isolated Extramedullary Relapse in Acute Lymphoblastic Leukemia: What Can We Do Before and After Transplant?
The case of a 43-year-old male with a history of B-cell acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Santiago Riviello-Goya, MD, Aldo A. Acosta-Medina, MD, Sergio I. Inclan-Alarcon, MD, Sofia Garcia-Miranda, MD, Christianne Bourlon, MD, MHSc Source Type: news

Joseph Wynne, MD, Discusses Developments in the Field of Acute Lymphoblastic Leukemia
The ALL expert spoke about new research in the field and how it has changed the landscape for this disease. (Source: CancerNetwork)
Source: CancerNetwork - January 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia
Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 21, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news

Dasatinib Tops Imatinib for Ph & #43; Acute Lymphoblastic Leukemia
TUESDAY, Jan. 21, 2020 -- Dasatinib is associated with improved survival for pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to a study published online Jan. 16 in JAMA Oncology. Shuhong Shen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2020 Category: Pharmaceuticals Source Type: news

Defining the Landscape of Mutations Present in Pediatric Acute Lymphoblastic Leukemia
This research has the potential to aid in the development of new strategies for early detection of relapse in pediatric patients with ALL, and the development of treatments to counter clinical occurrence. (Source: CancerNetwork)
Source: CancerNetwork - January 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Children treated for acute lymphoblastic leukemia may grow up to have heart problems, study finds
(Natural News) Acute lymphoblastic leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It is the most common type of cancer developed by children. Although ALL is known to progress quickly, advances in modern medicine have increased the survival rate of children with this disease. However, a recent study by researchers... (Source: NaturalNews.com)
Source: NaturalNews.com - December 24, 2019 Category: Consumer Health News Source Type: news

Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news

Immunotherapy drug improves outcomes for some children with relapsed leukemia
Blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 10, 2019 Category: American Health Source Type: news

Immunotherapy drug improves outcomes for some children with relapsed leukemia
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news

New approach to treating incurable leukemia in children discovered
(University of Zurich) Acute lymphoblastic leukemia is the most common form of cancer affecting children in Switzerland and, unfortunately, is often incurable. Researchers from the University of Zurich and the University Children's Hospital Zurich have now found a way to stop the driving force behind this type of leukemia at a molecular level and develop a targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2019 Category: Cancer & Oncology Source Type: news

Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL
In children with acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS) relapse, a higher dose of chemotherapy plus two extra doses of intrathecal therapy during early induction can obviate the need for prophylactic cranial irradiation, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling
Canonical Notch signaling relies on regulated proteolysis of the receptor Notch to generate a nuclear effector that induces the transcription of Notch-responsive genes. In higher organisms, one Notch-responsive gene that is activated in many different cell types encodes the Notch-regulated ankyrin repeat protein (NRARP), which acts as a negative feedback regulator of Notch responses. Here, we showed that NRARP inhibited the growth of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL) cell lines and bound directly to the core Notch transcriptional activation complex (NTC), requiring both the transcription factor RB...
Source: Signal Transduction Knowledge Environment - November 4, 2019 Category: Science Authors: Jarrett, S. M., Seegar, T. C. M., Andrews, M., Adelmant, G., Marto, J. A., Aster, J. C., Blacklow, S. C. Tags: STKE Research Articles Source Type: news

Exercise Intolerance May Harm Neurocognition in ALL Survivors
MONDAY, Oct. 21, 2019 -- For adult survivors of childhood acute lymphoblastic leukemia (ALL), exercise intolerance is associated with worse neurocognitive outcomes, according to a study published online Oct. 21 in Cancer. Nicholas S. Phillips, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2019 Category: Pharmaceuticals Source Type: news

Can More Exercise Improve Thinking Skills in Cancer Survivors?
MONDAY, Oct. 21, 2019 -- Boosting exercise capacity may protect the mental functioning of childhood leukemia survivors, according to a new study. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Due to their disease and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 21, 2019 Category: General Medicine Source Type: news

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Cancer sufferer, five, who has always wanted to be a tattoo artist lives out her dream
The five-year-old girl, known only as Maja, is battling acute lymphoblastic leukaemia. She visited a local tattoo parlour in Cleveland, Ohio, where she was shown all the tools. (Source: the Mail online | Health)
Source: the Mail online | Health - September 27, 2019 Category: Consumer Health News Source Type: news

Amgen announces positive results from two Phase 3 BLINCYTO ® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with (Source: World Pharma News)
Source: World Pharma News - September 25, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Micafungin As Antifungal Prophylaxis during Induction Phase of Chemotherapy in Pediatric Acute Lymphoblastic Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 21, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Medicare Now Covers CAR T-Cell Therapy for Approved Cancers
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - September 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news